These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27572411)

  • 1. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
    Barras MA; Serisier D; Hennig S; Jess K; Norris RL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care.
    Brockmeyer JM; Wise RT; Burgener EB; Milla C; Frymoyer A
    Pediatr Pulmonol; 2020 Dec; 55(12):3343-3350. PubMed ID: 32827334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
    Gao Y; Hennig S; Barras M
    Clin Pharmacokinet; 2019 Mar; 58(3):389-399. PubMed ID: 30140975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Forecasting for Intravenous Tobramycin Dosing in Adults With Cystic Fibrosis Using One Versus Two Serum Concentrations in a Dosing Interval.
    Drennan PG; Thoma Y; Barry L; Matthey J; Sivam S; van Hal SJ
    Ther Drug Monit; 2021 Aug; 43(4):505-511. PubMed ID: 33941739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
    Burgard M; Sandaradura I; van Hal SJ; Stacey S; Hennig S
    Clin Pharmacokinet; 2018 Aug; 57(8):1017-1027. PubMed ID: 29134570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V; Lind A; Rasmussen M; Coulthard K
    J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
    Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
    Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
    Imani S; Fitzgerald DA; Robinson PD; Selvadurai H; Sandaradura I; Lai T
    J Antimicrob Chemother; 2022 Nov; 77(12):3358-3366. PubMed ID: 36172897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis: an Update.
    Gao Y; Barras M; Hennig S
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.